Olmesartan inhibits the expression of monocyte chemoattractant protein-1 and tumor necrosis factor-α and improves vascular remodeling after vascular injury in mouse

Chinese Journal of Traumatology - English Edition

Volumn 7, Issue 1, 2004, Pages 56-61

  Li, Zhen ^a   Chen, Xiao Dong ^a   Ni, Shao Kai ^a   Li, Jian Wen ^a   Lin, Mu Sheng ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

Angiotensin II; Inflammation; Monocyte chemoattractant protein 1; Tumor necrosis factor

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BROXURIDINE; IMIDAZOLE DERIVATIVE; MONOCYTE CHEMOTACTIC PROTEIN 1; OLMESARTAN; POLYETHYLENE; TETRAZOLE DERIVATIVE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANALYSIS OF VARIANCE; ANGIOGENESIS; ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; BLOOD VESSEL INJURY; CELL CULTURE; CELL DIVISION; CELL PROLIFERATION; CONTROLLED STUDY; CUFF; CYTOLOGY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; EXPERIMENTAL MODEL; FEMORAL ARTERY; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; INTIMA; MALE; MINIPUMP; MONOCYTE; MORPHOMETRICS; MOUSE; MOUSE STRAIN; NONHUMAN; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROBABILITY; PROTEIN EXPRESSION; RECEPTOR BLOCKING; SENSITIVITY AND SPECIFICITY; SMOOTH MUSCLE FIBER; SYSTOLIC BLOOD PRESSURE; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

EID: 1142311612     PISSN: 10081275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-809.
2. Schwartz SM, deBlois D, O'brien ERM. The intima: soil for atherosclerosis and restenosis. Circ Res 1995;77:445-465.
3. Schwartz SM. Perspectives series: cell adhesion in vascular biology. Smooth muscle migration in atherosclerosis and restenosis. J Clin Invest 1997;99:2814-2816.
4. Powell JS, Clozel JP, Muller RK, et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989;245:186-188.
5. 1 receptor antagonist. Effects on smooth muscle cell migration and proliferation after balloon catheter injury. Am J Pathol 1991; 139:1291-1296.
6. Rakugi H, Wang DS, Dzau VJ, et al. Potential importance of tissue angiotensin-converting enzyme inhibition in preventing neointima formation. Circulation 1994;90:449-455.
7. Iwai N, Izumi M, Inagami T, et al. Induction of renin in medial smooth muscle cells by balloon injury. Hypertension 1997;29:1044-1050.
8. Rakugi H, Jacob HJ, Krieger JE, et al. Vascular injury induces angiotensinogen gene expression in the media and neointima. Circulation 1993;87:283-290.
9. Schmidt-Ott KM, Kagiyama S, Phillips MI. The multiple actions of angiotensin II in atherosclerosis. Regul Pept 2000;93:65-77.
10. Berk BC, Haendeler J, Sottile J. Angiotensin II, atherosclerosis, and aortic aneurysms. J Clin Invest 2000;105: 1525-1526.
11. 2 receptor expression and signaling. Physiol Genomics. 2000;2: 13-30.
12. Akishita M, Shirakami G, Iwai M, et al. Angiotensin converting enzyme inhibitor restrains inflammation-induced vascular injury in mice. J Hypertens 2001;19:1083-1088.
13. 2 receptor and vascular smooth muscle cell differentiation in vascular development. Hypertension 1999;33:1414-1419.
14. Gerrity RG. The role of the monocyte in atherogenesis, I: transition of blood-bome monocytes into foam cells in fatty lesions. Am J Pathol 1981;103:181-190.
15. Navab M, Imes SS, Hama SY, et al. Monocyte transmigration induced by modification of low-density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high-density lipoprotein. J Clin Invest 1991:2039-2046.
16. Randolph GJ, Furie MB. A soluble gradient of endogenous monocyte chemoattractant protein-1 promotes the transendothelial migration of monocytes in vitro. J Immunol 1995;155:3610-3618.
17. Takeya M, Yoshimura T, Leonard EJ, et al. Detection of monocyte chemoattractant protein-1 in human atherosclerotic lesions by an anti-monocyte chemoattractant protein-1 monoclonal antibody. Hum Pathol 1993;24:534-539.
18. Nelken NA, Coughlin SR, Gorden D, et al. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 1991;88:1121-1127.
19. Harada K, Komuro I, Sugaya T, et al. Vascular injury causes neointimal formation in angiotensin II type 1a receptor knockout mice. Circ Res 1999;84:179-185.
20. Chen XL, Tummala PE, Olbrych MT, et al. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res 1998; 83:952-959.
21. Wu L, Iwai M, Nakagami H, et al. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation 2001;104:2716-2721.
22. Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 1999;33:613-621.
23. Martin T, Cardarelli PM, Parry GC, et al. Cytokine induction of monocyte chemoattractant protein-1 gene expression in human endothelial cells depends on the cooperative action of NF-kappaB and AP-1. Eur J Immunol 1997;27:1091-1097.
24. Marumo T, Schini-Kerth VB, Busse R. Vascular endothelial growth factor activates nuclear factor-kappaB and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells. Diabetes 1999;48:1131-1137.
25. Mercurio F, Zhu H, Murray BW, et al. IKK-1 and IKK-2: Cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science 1997;278:860-866.